Evaluation of clinical events and costs associated with the addition of dapagliflozin to chronic kidney disease treatment: Cost offset analysis Juan Francisco Navarro-González; Alberto Ortiz; Ana Cebrián Cuenca; Lluís Segú; Belén Pimentel; Unai Aranda; Blanca Lopez-Chicheri; Margarita Capel; Elisenda Pomares Mallol; Christian Caudron; Juan José García Sánchez; Roberto Alcázar Arroyo;

Projection of the clinical and economic burden of chronic kidney disease between 2022 and 2027 in Spain: Results of the Inside CKD project Juan F. Navarro González; Alberto Ortiz; Ana Cebrián Cuenca; Marta Moreno Barón; Lluís Segú; Belén Pimentel; Unai Aranda; Blanca Lopez-Chicheri; Margarita Capel; Elisenda Pomares Mallol; Christian Caudron; Juan José García Sánchez; Roberto Alcázar Arroyo;

Does uric acid-lowering treatment slow the progression of chronic kidney disease? A meta-analysis of randomized controlled trials Paulo Roberto Bignardi; Danielle Harumi Ido; Felipe Augusto Lopes Garcia; Lucas Mendes Braga; Vinicius Daher Alvares Delfino;